Inotec AMD Limited

Inotec AMD Limited is a United Kingdom medical technology company based in Cambridge, known commercially through its NATROX® wound care brand. The company develops and markets NATROX® O₂, a medical device that delivers continuous topical oxygen therapy (cTOT) to chronic and hard-to-heal wounds. According to the company, the technology was born from a personal quest: the inventor, referred to as Mel, sought a way to help an aunt suffering from a painful venous leg ulcer that refused to heal. After researching wound healing and concluding that oxygen was central to the process, he and a small team — with input from contacts at the University of Cambridge — developed a method to deliver oxygen to a wound without applying pressure or chemicals to the skin. They then formed a company with the mission of developing innovative medical technology to help patients. The flagship product, NATROX® O₂, is a wearable, non-invasive system consisting of an Oxygen Delivery System (ODS) and an Oxygen Generator (OG). The ODS is a sterile, single-use interface with a proprietary 'wheel' shape made from a soft, triple-layer, pliable material that conforms to the wound bed, allows exudate to pass into a secondary dressing, and optimizes oxygen flow. The Oxygen Generator produces a continuous flow of oxygen 24/7 through water electrolysis. The device is powered by two rechargeable batteries, each lasting a full day, which the patient swaps daily; it starts automatically when a battery is clicked in, with no buttons, alarms, or menus. The company positions the device as small, lightweight, discreet, and compatible with most standard secondary dressings and across clinical and home care settings. Inotec AMD markets NATROX® O₂ internationally to healthcare professionals and health systems, emphasizing the growing body of clinical evidence and guideline support for continuous topical oxygen therapy. The company's website highlights recommendations and endorsements from a range of expert bodies, including the 2024 Wound Healing Society guidance (which recognized TOT at the highest level of evidence, Level 1), the 2023 IWGDF guidance, the ADA Standards of Care for Diabetes 2026 (an 'A grade' recommendation for chronic diabetic foot ulcers), a 2023 International Consensus, a Health Technology Assessment for Wales, a new algorithm for DFU management, and a Delphi Consensus in South America. The company also cites a finding that patients with a chronic wound have a 71% greater chance of healing using NATROX® O₂ continuous topical oxygen therapy than with standard of care alone. The company operates as a private entity and presents itself as mission-driven, stating that its goal is to transform the quality of life for anyone with a chronic wound because everyone deserves the chance to heal. Its commercial identity is closely tied to the NATROX® brand, and its public communications focus on clinical evidence, global expert recommendations, and the practical usability of its wearable oxygen therapy device.

Inotec AMD Limited is a Cambridge, United Kingdom-based medical technology company whose commercial identity centers on the NATROX® wound care brand. The company's origin story, as told on its website, begins with the inventor of its topical oxygen technology, referred to as Mel, whose aging aunt suffered for months from a painful venous leg ulcer that would not heal. Motivated to relieve her daily misery, Mel set out to understand how wounds heal and concluded that oxygen was the secret to healing. The central challenge was to deliver oxygen near a wound without applying pressure or chemicals to the skin, so as to avoid negative side effects. After consulting friends at the University of Cambridge, the inventor and his small team masterminded the technology now known as NATROX® O₂. This topical oxygen therapy leverages the natural properties of oxygen to stimulate healing. To share the solution, they formed a company with a mission to develop innovative medical technology designed to help patients, recognizing that many others faced the same struggle with hard-to-heal wounds. The company's flagship product, NATROX® O₂, is a medical device that uses the natural properties of oxygen to stimulate healing in previously non-healing wounds. It is described as non-invasive, comfortable, wearable, and highly effective. The system comprises two main components: the Oxygen Delivery System (ODS), a sterile, single-use interface with a proprietary 'wheel' shape made from a soft, triple-layer, pliable material that conforms to the wound bed, allows free passage of exudate into the secondary dressing, and optimizes oxygen flow; and the Oxygen Generator (OG), which delivers a continuous flow of oxygen 24/7 to the wound bed through water electrolysis. The device is powered by two rechargeable batteries, each lasting a full day, which the patient swaps daily. It starts automatically when a battery is clicked in, with no buttons, alarms, or menus, and is designed to be small, wearable, lightweight, and discreet, giving patients freedom of movement. It is compatible with most standard secondary dressings and can be used during any phase of healing and across clinical and home care settings. Over time, the company has built its market position around clinical evidence and guideline support for continuous topical oxygen therapy (cTOT). Its website highlights a growing number of international guidelines and expert recommendations, including the 2024 Wound Healing Society guidance, which specifically recognized TOT and is supported by the highest level of evidence (Level 1); the 2023 IWGDF guidance, which states that topical oxygen may be considered as an adjunct therapy to standard of care for wound healing where standard of care alone has failed; the ADA Standards of Care for Diabetes 2026, which gives TOT an 'A grade' recommendation for the third year as an adjunct treatment for chronic diabetic foot ulcers (DFUs); a 2023 International Consensus endorsing adjunctive administration of TOT for hard-to-heal wounds; a Health Technology Assessment for Wales stating that cTOT should be adopted in Wales; a new algorithm for DFU management stating that all hard-to-heal wounds are likely to benefit from TOT, even after revascularization; and a Delphi Consensus in South America supporting the efficacy and safety of cTOT in treating chronic, difficult-to-heal ulcers. The company also cites evidence that patients with a chronic wound have a 71% greater chance of healing using NATROX® O₂ continuous topical oxygen therapy than with standard of care alone. Today, Inotec AMD presents itself as a mission-driven organization whose team shares a passion for health care and compassion for patients, with the stated mission to transform the quality of life for anyone with a chronic wound because everyone deserves the chance to heal. The company continues to promote NATROX® O₂ internationally and to direct healthcare professionals to the clinical evidence supporting continuous topical oxygen therapy.

• Inventor Mel begins developing a topical oxygen technology after his aunt suffers from a non-healing venous leg ulcer.

• After consulting friends at the University of Cambridge, Mel and his small team mastermind the technology now known as NATROX® O₂.

• The team forms a company with a mission to develop innovative medical technology to help patients.

• 2023 International Consensus endorses adjunctive administration of TOT for hard-to-heal wounds.

• 2023 IWGDF guidance states topical oxygen may be considered as an adjunct therapy to standard of care where standard of care alone has failed.

• 2024 Wound Healing Society guidance specifically recognizes TOT, supported by the highest level of evidence (Level 1).

• ADA Standards of Care for Diabetes 2026 gives TOT an 'A grade' recommendation for the third year as an adjunct treatment for chronic DFUs.

Developer and marketer of advanced, evidence-backed wearable topical oxygen therapy for chronic and hard-to-heal wounds, positioned for use across the care continuum including home care.

• NATROX® O₂ Continuous Topical Oxygen Therapy (cTOT)

  A wearable, non-invasive medical device that uses the natural properties of oxygen to stimulate healing in previously non-healing wounds. It is designed for use across clinical and home care settings and is compatible with most standard secondary dressings.

• Oxygen Delivery System (ODS)

  A sterile, single-use interface with a proprietary 'wheel' shape made from a soft, triple-layer, pliable material that conforms to the wound bed, allows free passage of exudate into the secondary dressing, and optimizes oxygen flow.

• Oxygen Generator (OG)

  Delivers a continuous flow of oxygen 24/7 to the wound bed through water electrolysis. Powered by two rechargeable batteries, each lasting a full day, which the patient swaps daily. Starts automatically when a battery is clicked in; no buttons, alarms, or menus.

1. 1NATROX® Wound Care | Continuous Topical Oxygen Therapynatroxwoundcare.com
2. 2NATROX® Wound Care | About Usnatroxwoundcare.com
3. 3NATROX® Wound Care O₂ | Advanced Topical Oxygen Therapy - Product Overviewnatroxwoundcare.com
4. 4Inotec AMD Limited (United Kingdom) - Wikidatawikidata.org